Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

dent for Business Development added: "Our research and preclinical development teams have done an excellent job in advancing the program since January of this year. Bayer Schering Pharma's early option exercise is a recognition of Micromet's development capabilities and confirms the promise of our BiTE antibody platform."

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... 26, 2015 "Whether it,s our family, our ... In a single sentence, Dr. Anthony ... at Pfizer,s Centers for Therapeutic Innovation (CTI), ... progress at America,s biopharmaceutical companies. CTI,s ... academia, patient foundations and the National Institutes of Health ...
(Date:3/26/2015)... Mich. , March 26, 2015 Cardiologists ... have performed the Midwest,s first commercial implant of a ... for patients with non-valvular atrial fibrillation. The Watchman Left ... use of blood-thinning warfarin medication to reduce the risk ... common heart rhythm disorder affecting more than 5 million ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... 2015 Ticket Down is a reputable source for ... After a phenomenal and highly successful live tour last year, ... out on tour again in 2015 and they will be visiting ... April 29th in New York City at the cozy Beacon Theatre ... on May 10th. , Fans of the hit show can look ...
(Date:3/27/2015)... BC (PRWEB) March 27, 2015 According ... ( http://www.idataresearch.com ), the plate and screw market in ... in the generic plate and screw segment. Price decreases ... market. Despite representing almost 50% of the total European ... to decrease the total market value, year after year. ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 GrassrootsHealth, ... its Protect Our Children (POC) NOW! vitamin D demonstration ... Medical University of South Carolina (MUSC), and will soon ... be available at no cost to a minimum of ... who live within these two service areas. The project ...
Breaking Medicine News(10 mins):Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4
... categories for// printed letters and sounds, says a new study. ... filter out visual disturbances that may obscure the pattern of ... scientists from University of Southern California, US, brings out a ... dyslexic brain. ,Dyslexia is a learning disorder in ...
... lose knee lubrication following an injury to the knee. This ... of Rhode Island had identified a way to find out ... after a knee injury, in order to find out whether ... ,Although knee injury is considered to be a risk factor ...
... based study had found that children are more exposed ... anywhere else. ,Allergens that are commonly found indoor ... dust and dust mites, cockroaches and pollens. These may ... and various other diseases. Some of the symptoms experienced ...
... People who have survived cancer may have higher risks ... ,Researchers from University of Southern California had found ... long life have twice as much risk as their ... have studied 702 survivors of cancer and their twins ...
... in conceiving and// delivering world’s first baby born from ... the baby had her eggs collected from her, frozen ... fertilized from sperms of her partner through in-vitro fertilization ... in her uterus, which she carried to a full ...
... to air pollutions of big// cities may harm their ... of polluted air of the metros can change the ... from the cars, trucks, buses, tobacco smoke, combustion etc ... of the fetus. , ,The research conducted by ...
Cached Medicine News:
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... is an immunochromatography based one step ... qualitative determination of amphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... fully automated, user-friendly system that helps ... and improve patient care. This state-of-the-art ... testing capabilities with a complete menu ... also a powerful, intuitive system that ...
... in-vitro diagnostic test kit for the ... in human serum/plasma. This test is ... gelatin particles coated with inactivated Trypanosoma ... are agglutinated in the presence of ...
Medicine Products: